Skip to content
Subscriber Only

Reckitt Benckiser Says Its On Track to Meet its Goals

Reckitt Benckiser Group Plc, the maker of Lysol disinfectants, said a separate stock listing is a “strong option” for its pharmaceutical business as it posted first-quarter revenue growth that matched analysts’ estimates.

Non-pharmaceutical sales rose 4 percent, excluding acquisitions, disposals and currency moves, the Slough, England-based company said today in a statement, matching the median estimate of 11 analysts surveyed by Bloomberg. A spinoff or initial public offering of the pharmaceutical unit, rather than a sale of the business, “is emerging” as a possible option, the company said.